One of the most consequential prescribing decisions of the past two decades was based on evidence that was valid, but applied too broadly. The correction has been slow, and the consequences have been measurable.

The Synthesis: In 2002, the Women's Health Initiative, a large randomised controlled trial, reported that combined estrogen-progestin therapy was associated with increased rates of breast cancer, coronary heart disease, and stroke. Within months of the study's publication, prescriptions fell sharply around the world. The reaction was understandable given what clinicians knew at the time. However, two decades of research have since shown that the study's findings were applied to many women who were very different from those in the original research study.

The trial enrolled women with an average age of 63, most of whom were more than a decade past menopause. The relationship between hormone therapy and cardiovascular risk appears to depend critically on timing. Re-examinations of the original trial data, multiple independent cohort studies, and updated guidance from the North American Menopause Society and the British Menopause Society now reflect a broadly consistent conclusion: women who start hormone therapy before age 60 and within ten years of their final menstrual period generally show a more favorable balance of benefits and risks than the average participant in the original Women's Health Initiative trial (many of whom were older and likely had more advanced vascular disease than women entering menopause).

The Calibration: The 2002 findings were often treated as a near-universal warning against hormone therapy. But for younger women who had recently entered menopause, the risk profile was quite different. For women under 60 who are within ten years of menopause and have significant symptoms, current evidence now supports a far more favorable benefit-risk balance than the one many clinicians took from the original headlines. In hindsight, the overcorrection was substantial: many women with significant symptoms went untreated or undertreated as concerns from one group of women were often generalized to another.

The Synthesis: Conversations about modifiable dementia risk usually focus on behavior: sleep, exercise, social engagement, and treating hearing loss. There is now enough evidence to include air pollution in that same conversation. One pollutant of particular concern is fine particulate matter, known as PM2.5. These microscopic particles are produced largely by vehicle exhaust and combustion. The 2020 Lancet Commission on dementia prevention, intervention, and care identified outdoor air pollution as one of twelve modifiable risk factors for dementia, estimating that it accounts for about 2% of dementia cases worldwide. That figure sits in the same order of magnitude as physical inactivity, obesity, and excessive alcohol use.

The Lancet report synthesized evidence from large cohort studies across several countries, including analyses using US Medicare data and UK Biobank participants. Across these studies, long-term exposure to air pollution was consistently associated with faster cognitive decline, reduced brain volume, and increased dementia incidence. The proposed biological pathways are multiple and independently plausible. Fine particles can trigger inflammation in the brain, accelerate cerebrovascular disease, and may have direct toxic effects on the nervous system. Together, the consistency across populations and mechanisms suggests this is no longer an early-stage signal.

The Calibration: This evidence is not yet as definitive as a controlled trial, and confounding factors are difficult to eliminate entirely in environmental exposure research. That said, the consistency of the findings and the plausibility of the biological mechanisms are now sufficient to move air pollution into dementia prevention frameworks. At the individual level, full control of ambient air quality is not possible. However, at the policy level, clean air standards now rest on a brain health evidence base that extends well beyond respiratory disease.

The Synthesis: Time-restricted eating is a form of intermittent fasting that restricts food intake to a shortened window within each 24-hour period. The approach has gained popularity partly because it is simple to follow and may help some people adhere to a weight-loss plan. Earlier observational and pilot studies suggested that meal timing and shortened eating windows might be linked to weight loss or metabolic improvement, but the evidence was not strong enough to support firm clinical guidance.

Randomised controlled trials have since tested the claim more directly. When total calorie intake is matched across groups, time-restricted eating does not appear to produce meaningful additional weight loss beyond calorie restriction alone. In a 2022 randomised controlled trial published in the New England Journal of Medicine, adults with obesity were assigned to calorie restriction with or without an 8-hour eating window. After 12 months, there were no significant differences in body weight, body fat, blood pressure, glucose, lipid levels, or other cardiometabolic outcomes between the two approaches. The apparent metabolic advantage attributed to timing alone is not supported once calories are controlled.

The Calibration: Time-restricted eating remains a practical tool in cases where a defined eating window helps reduce overall intake and sustain consistency. That mechanism is credible and useful. It may also improve some metabolic markers when it leads to lower calorie intake. But when calories are matched, it has not been shown to offer a reliable metabolic advantage over standard calorie restriction. The more accurate interpretation is that time-restricted eating may work by helping some people eat less, not because the eating window itself reliably produces greater weight loss.

Treatments regularly improve measurable biological variables: lower low-density lipoprotein (LDL) cholesterol, higher bone density, or reduced fasting glucose. Those changes are often assumed to produce better health outcomes. Medicine has learned through repeated experience that the assumption does not always hold true.

The concept involved is the surrogate endpoint: a measurable variable assumed to predict an outcome the patient actually cares about, such as a heart attack or a fracture. The surrogate is assumed to track the clinical outcome because the biological relationship appears well established. Yet even a well-established biological relationship is not proof of clinical benefit, and the body is not a linear system. Changing one variable can trigger other effects that cancel or even reverse the expected benefit.

Torcetrapib, a cholesterol-modifying drug, raised levels of high-density lipoprotein (HDL), a marker long associated with lower cardiovascular risk, by 72% in clinical trials. The trial was halted because the drug increased mortality. Another HDL-raising agent, niacin, produced the expected biomarker result in multiple large trials and failed to reduce cardiovascular events. Both drugs were doing exactly what they were designed to do biologically. However, the biology did not translate to clinical benefit.

The same pattern appears across domains. Supplements routinely marketed on mechanistic grounds offer a compound that raises or restores some biological marker associated with health or aging, and that improvement is treated as equivalent to the clinical outcome the marker is assumed to predict. The two are not the same. A treatment supported only by surrogate improvement is not evidence of clinical benefit. It is a hypothesis about clinical benefit. It may prove correct, but it has not yet done so. Recognizing the distinction is one of the most reliable ways to evaluate health claims, particularly when a treatment is being sold on what it changes rather than on what it actually achieves.

The Claim: Chronic stress depletes the adrenal glands, producing a condition described as adrenal fatigue that can be identified through cortisol testing and addressed with targeted supplements.

The Distortion: Adrenal fatigue is not a recognized diagnosis in endocrinology. Established clinical entities such as primary adrenal insufficiency (including Addison's disease) are rare, well-defined disorders caused by impaired hormone production, not cumulative everyday stress. Cortisol follows a strong diurnal rhythm and is highly responsive to sleep patterns, acute illness, food intake, physical activity, and psychological stress. Due to this variability, isolated or single time point cortisol measurements are not reliable as standalone diagnostic tools for explaining non-specific symptoms such as fatigue, poor sleep, or reduced concentration. The gap between the marketed concept of adrenal fatigue and recognized endocrine disease is substantial.

The Calibration: Fatigue, difficulty concentrating, and disrupted sleep are legitimate symptoms that warrant clinical attention. However, the proposed mechanism of chronically "depleted" adrenal glands is not supported by endocrine physiology. A more accurate framing is that these symptoms are non-specific and require evaluation for established causes rather than interpretation through a diagnostic label that lacks clinical validity.

The Claim: Oral collagen supplements rebuild joint cartilage and improve skin elasticity by supplying the body with the collagen it needs.

The Distortion: Collagen is broken down during digestion into amino acids and small peptides, like any other dietary protein. While some studies suggest these peptides may influence collagen turnover or signalling pathways, there is no clear mechanism showing that ingested collagen is preferentially routed to rebuild skin or joint cartilage in the way marketing implies. A number of trials report modest improvements in skin hydration or elasticity measures, and some studies in joint pain show small reductions in symptoms, but findings are often short-term, and frequently funded by supplement manufacturers.

The Calibration: Adequate total protein intake supports the body's own collagen synthesis. No evidence establishes that collagen supplements outperform equivalent protein from food sources for joint or skin outcomes.

Stay calibrated.

If The Calibration brought you a clearer perspective today, forward it to someone who values the same.

Received this from a friend or colleague? Subscribe here to get it directly.

Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. Journal of the American Medical Association, 2002.

The 2022 Hormone Therapy Position Statement of the North American Menopause Society. Menopause: The Journal of The North American Menopause Society, 2022.

BMS & WHC's 2020 Recommendations on Hormone Replacement Therapy in Menopausal Women. British Menopause Society, 2020.

Dementia Prevention, Intervention, and Care: 2020 Report of the Lancet Commission. The Lancet, 2020.

Air Pollution and Dementia: A Systematic Review. Journal of Alzheimer's Disease, 2019.

Calorie Restriction with or without Time-Restricted Eating in Weight Loss. New England Journal of Medicine, 2022.

Effects of Torcetrapib in Patients at High Risk for Coronary Events. New England Journal of Medicine, 2007.

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England Journal of Medicine, 2011.

The Calibration is an editorially curated health briefing. Content is drawn from published research and credible sources for informational purposes only. It does not constitute medical advice, clinical guidance, diagnosis, or treatment, and is not a substitute for consultation with a qualified healthcare professional. Nothing in this briefing should be used to make health or treatment decisions or to delay seeking professional medical advice.

Sponsored content, when present, will always be clearly identified.